CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)

Vaccine

Volumn 19, Issue 32, 2001, Pages 4874-4882

  Hancock, Gerald E ^a   Heers, Kristen M ^a   Smith, Jason D ^a   Scheuer, Catherine A ^a   Ibraghimov, Alexander R ^a   Pryharski, Karin S ^a  

^a PFIZER INC   (United States)

Author keywords

Eosinophils; Fusion (F) protein; Oligodeoxynucleotides (ODN); Respiratory syncytial virus (RSV); Subunit vaccines; Type 1 T cells; Unmethylated CpG

Indexed keywords

ALUMINUM HYDROXIDE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 5; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PROTEIN P35; VIRUS VACCINE;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELL COMPARTMENTALIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; EOSINOPHILIA; FEMALE; IMMUNE RESPONSE; INFLAMMATORY CELL; KNOCKOUT MOUSE; LUNG INFECTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STATISTICAL ANALYSIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CPG ISLANDS; DIMERIZATION; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-5; KILLER CELLS; LUNG; METHYLATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PNEUMONIA, VIRAL; PROTEIN SUBUNITS; PULMONARY EOSINOPHILIA; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SPLEEN; VACCINATION; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0035860575     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00228-6     Document Type: Article

References (41)

1. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment
2. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7
3. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
4. Respiratory syncytial virus infection in adults
5. Respiratory syncytial virus vaccines
6. The serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines co-formulated with natural fusion and attachment proteins of respiratory syncytial virus
7. An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children vaccinated with an inactivated RS virus vaccine
8. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
9. Distinct types of lung disease caused by functional subsets of antiviral T cells
10. + T cells
11. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus
12. + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection
13. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine
14. Advances in vaccine adjuvants
15. The role of CpG motifs in innate immunity
16. IL-12 as an adjuvant for cell-mediated immunity
17. + T cells
18. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection
19. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein or respiratory syncytial virus
20. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12
21. CpG motifs in bacterial DNA trigger direct B-cell activation
22. Immunological tolerance of the mouse IgE system: Dissociation between T cell tolerance and suppressor cell activity
23. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
24. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins
25. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
26. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
27. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
28. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines
29. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism
30. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice
31. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
32. Lymphokine control of in vivo immunoglobulin isotype selection
33. T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice
34. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection
35. Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity
36. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
37. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
38. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1(Th1) immunity
39. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12-and IFN-gamma-dependent mechanisms
40. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or infection
41. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine